National Cancer Institute Home at the National Institutes of Health |
Please wait while this form is being loaded....
The Applied Research Program Web site is no longer maintained. ARP's former staff have moved to the new Healthcare Delivery Research Program, the Behavioral Research Program, or the Epidemiology & Genomics Research Program, and the content from this Web site is being moved to one of those sites as appropriate. Please update your links and bookmarks!

Publication Abstract

Authors: Harlan LC, Klabunde CN, Ambs AH, Gibson T, Bernstein L, McTiernan A, Meeske K, Baumgartner KB, Ballard-Barbash R

Title: Comorbidities, therapy, and newly diagnosed conditions for women with early stage breast cancer.

Journal: J Cancer Surviv 3(2):89-98

Date: 2009 Jun

Abstract: PURPOSE: To describe comorbidities in breast cancer patients at diagnosis and examine factors associated with self-reported comorbidities 30 months post-diagnosis. METHODS: Nine hundred forty one of 1,171 women had a medical record abstract and a follow-up survey in the Health, Eating, Activity and Lifestyle Study. RESULTS: We compared our breast cancer cohort to a contemporaneous nationally-representative sample of age, race/ethnicity and education matched women without cancer (n = 865). Breast cancer patients did not have substantially more comorbidities than women without breast cancer. Women with a hospital record of congestive heart failure significantly less often received chemotherapy or radiation following breast conserving surgery. In multivariate analysis, women who received chemotherapy alone (OR = 3.2; 95% CI: 1.5-6.8), chemotherapy plus radiation (OR = 1.9; 95% CI: 1.02-3.7) or radiation plus tamoxifen (OR = 1.9; 95% CI: 1.1-3.2) were significantly more likely to report at least one new comorbid condition following breast cancer diagnosis than women who received no chemotherapy, tamoxifen or radiation. Overall, women who received adjuvant therapy were more likely to have new comorbidities. CONCLUSIONS: Comorbidities were not substantially different in breast cancer patients than the non-cancer matched controls. Future research should focus on efforts to minimize comorbidities related to chemotherapy and other combination therapy.

Last Modified: 03 Sep 2013